Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma Clinical Trial

Official title:

Application of Tranilast as a Radiosensitizer in the Treatment of Radiotherapy Resistant Nasopharyngeal Carcinoma: a Phase II Clinical Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05626829
• Other study ID #: NFEC-2022-270
• Status: Recruiting
• Phase: Phase 2
• Start date: July 20, 2022
• Est. completion date: November 30, 2024

Study information

• Verified date: October 2023
• Source: Nanfang Hospital, Southern Medical University
• Contact: Guan Jian, Ph.D.
• Phone: +86-1363210224
• Email: 51643930[@]qq.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Nasopharyngeal carcinoma is one of the high incidence head and neck cancer in Southeast Asia. Radiotherapy is the main treatment for nasopharyngeal carcinoma, and its response rate can reach 80~90%. However, for radiotherapy resistant patients with metastasis and recurrence, the survival prognosis decreased significantly, and the 5-year overall survival rate was only 20% - 40%. Tranilast is an anti-allergic drug, which is clinically used to treat bronchial asthma and can inhibit fibroblasts α- SMA and type I collagen expression. Through experiments in vivo and in vitro, the investigators' research group has proved that Tranilast can inhibit the activity of tumor related fibroblasts, reduce the radiotherapy resistance of nasopharyngeal carcinoma, and has the radiosensitizing effect of nasopharyngeal carcinoma. This result has been published in J exp Clin cancer res (if=11.16). The investigators plan to carry out the clinical transformation of basic research, carry out a prospective intervention phase II clinical trial, compare the objective remission rate of patients with recurrent nasopharyngeal carcinoma treated with previous radiotherapy, and explore the safety and effectiveness of using Tranilast as a radiotherapy sensitizer for radiotherapy to resist the treatment of nasopharyngeal carcinoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 18
• Est. completion date: November 30, 2024
• Est. primary completion date: July 20, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Sign informed consent

2. At least 18 years old on the date of signing the informed consent

3. Previously received standard radical radiotherapy and chemotherapy

4. Recurrent nasopharyngeal carcinoma in situ or cervical lymph nodes confirmed by pathological biopsy and imaging examination

5. After multidisciplinary consultation, there was a clear indication for surgery, and the patient was informed and refused to accept surgical treatment 6)ECOG PS:0/1

7) Laboratory examination confirmed good organ function, which should be carried out within 10 days before the first treatment.

Exclusion Criteria:

1. After evaluation, it does not meet the indications of re-radiotherapy

2. unable to take oral medication

3. Pregnancy or lactation

4. Known allergy to Tranilast

5. Patients who are judged by the researcher as unsuitable to participate in this trial

Related Conditions & MeSH terms

• Carcinoma
• Nasopharyngeal Carcinoma
• Recurrence
• Recurrent Cancer

Intervention

Drug:
• Tranilast
Tranilast capsules 100mg 3 times per day when reradiation

Locations

Country	Name	City	State
China	Southern medical university	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Jian Guan

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the Effectiveness of Tranilast in reradiation of recurrent nasopharyngeal carcinoma	we use the objective response rate (ORR), according to the RESIST v1.0	12 weeks after Tranilast treatment
Secondary	the Safety of Tranilast in reradiation of recurrent nasopharyngeal	treatment-related adverse events will be assessed by CTCAE v4.0	12 weeks after Tranilast treatment